Physician

General Surgery

Samuel Beenken is an expert in the field of General Surgery. He has 1 awards "Fellow (FACS)". Dr. Samuel W. Beenken is also a published doctor. He has 30 publication published. The most recent publication is: Models for early chemoprevention trials in breast cancer.

Publications

---

• Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.
• Treatment options for Merkel cell carcinoma.
• Therapy for calciphylaxis: an outcome analysis.
• Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer.
• Transforming growth factor-alpha: a surrogate endpoint biomarker?
• Long-term complications of breast-conservation therapy: can the incidence be reduced?
• Factors associated with local recurrence after skin-sparing mastectomy and immediate breast reconstruction for invasive breast cancer.
• Desmoplastic melanoma. Histologic correlation with behavior and treatment.
• Prognostic factors in patients dying of well-differentiated thyroid cancer.
• An intron binding protein is required for transformation ability of p53.
• Inhibition of the mutant p53 gene in transformation assays.
• Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer.
• Risk biomarker assessment for breast cancer progression: replication precision of nuclear morphometry.
• Bayesian monitoring of phase II trials in cancer chemoprevention.
• Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck.
• Workup of a patient with a mass in the neck.
• CD44 expression in dysplastic epithelium and squamous-cell carcinoma of the esophagus.
• Prognostic factors in minor salivary gland cancer.
• Models for early chemoprevention trials in breast cancer.
• Extent of surgery for intermediate-risk well-differentiated thyroid cancer.
• Biomarkers for breast cancer.
• Retinoid modulation of biomarkers in oral leukoplakia/dysplasia.
• Prognostic significance of cervical lymph node metastases in differentiated thyroid cancer.
• T1 and T2 squamous cell carcinoma of the oral tongue: prognostic factors and the role of elective lymph node dissection.
• Sentinel node biopsy for cutaneous melanoma in the head and neck.
• Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.
• Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid.
• Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases.
• 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers.

Schools

---

• University Of Manitoba Faculty Of Medicine

• Manitoba Affil Teach Hosps

• Manitoba Canc Found

• University Manitoba

• MD Anderson Canc Center

Doctors Specialties

---

• General Surgery

Accepted Insurances

---

• MultiPlan PPO
• PHCS Network PPO

Awards

---

• Fellow (FACS)

Education

---

• University of Manitoba

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Peter D. Ray, MD This Doctor is OpenDoctor Recommended.
	Dr. Benjamin M. McGrew, MD This Doctor is OpenDoctor Recommended.
	Dr. Edgar S. Frey, MD This Doctor is OpenDoctor Recommended.
	Dr. Thomas C. Matthews, MD
	Dr. William E. Riley, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael J. Hanaway, MD This Doctor is OpenDoctor Recommended.
	Dr. John G. Touliatos, MD This Doctor is OpenDoctor Recommended.
	Dr. Ashley L. Augspurger, MD This Doctor is OpenDoctor Recommended.
	Dr. Caroline E. Jones, MD
	Dr. Naveen Singanamala, MD
	Dr. William N. Viar Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Winn H. Mathews, MD
	Dr. Heather Waldrop, MD
	Dr. Patrick C. Yu, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog